

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Medical technologies evaluation programme

Equality impact assessment: Guidance development

GID-MT565 Optilume for treating recurrent bulbar urethral strictures

The impact on equality has been assessed during this evaluation according to the principles of the [NICE Equality scheme](#).

Medical technology consultation document

1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how?

No equality issues were identified during the scoping process.

Equality considerations: Optilume is intended for men with recurrent bulbar urethral strictures. These can be caused by injury to the penis, surgery or infection. Some people may not identify as men but have a penis. Urethral strictures become more common in people over 55. Sex, gender reassignment and age are protected characteristics under the Equality Act (2010). The clinical experts noted that trans women, with or without gender reassignment, have a bulbar urethra. If a bulbar stricture occurs, this is managed in the same way as for cisgender men. They considered that the evidence is generalisable to this group. This is stated in section 4.8 of the MTCD.

2. Have any other potential equality issues been highlighted in the sponsor's submission, or patient organisation questionnaires, and, if so, how has the committee addressed these?

No further equality issues were highlighted in the submission or patient organisation questionnaires.

3. Have any other potential equality issues been identified by the committee and, if so, how has the committee addressed these?

No other potential equality issues or considerations were identified by the committee.

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to or difficulties with access for the specific group?

No.

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No.

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

N/A.

7. Have the committee's considerations of equality issues been described in the medical technology consultation document, and, if so, where?

Yes, these have been discussed in section 4.8 of the MTCD.

Approved by Associate Director: Anastasia Chalkidou

Date: 10/06/2022

Medical technology guidance document

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the committee addressed these?

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to access for the specific group?

3. If the recommendations have changed after consultation, is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?

5. Have the committee's considerations of equality issues been described in the medical technology guidance document, and, if so, where?

Approved by Programme Director:

Date: